About Disc Medicine, Inc.
https://www.discmedicine.comDisc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases.
CEO
John D. Quisel
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-12-30 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 126
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Raymond James
Strong Buy
Truist Securities
Buy
HC Wainwright & Co.
Buy
Stifel
Buy
Wedbush
Outperform
BMO Capital
Outperform
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
FMR LLC
Shares:4.94M
Value:$380.4M
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC
Shares:2.14M
Value:$165.15M
BLACKROCK, INC.
Shares:2.02M
Value:$155.65M
Summary
Showing Top 3 of 177
About Disc Medicine, Inc.
https://www.discmedicine.comDisc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $67.61M ▲ | $-62.32M ▼ | 0% | $-1.77 ▼ | $-61.22M ▼ |
| Q2-2025 | $0 | $61.41M ▲ | $-55.25M ▼ | 0% | $-1.58 ▼ | $-54.2M ▼ |
| Q1-2025 | $0 | $39.95M ▲ | $-34.09M ▼ | 0% | $-1.02 ▼ | $-33.05M ▼ |
| Q4-2024 | $0 | $34.54M ▲ | $-29.46M ▼ | 0% | $-0.98 ▼ | $-13.25M ▲ |
| Q3-2024 | $0 | $32.86M | $-26.6M | 0% | $-0.89 | $-32.84M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $615.92M ▼ | $630.46M ▼ | $57.07M ▲ | $573.39M ▼ |
| Q2-2025 | $649.97M ▼ | $665.06M ▼ | $50.9M ▲ | $614.16M ▼ |
| Q1-2025 | $694.66M ▲ | $709.27M ▲ | $48.9M ▼ | $660.36M ▲ |
| Q4-2024 | $489.88M ▲ | $496.77M ▲ | $53.19M ▲ | $443.59M ▼ |
| Q3-2024 | $487.36M | $495.14M | $27.18M | $467.96M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-62.32M ▼ | $-47.8M ▲ | $49.54M ▼ | $11.59M ▲ | $13.33M ▲ | $-47.83M ▲ |
| Q2-2025 | $-55.25M ▼ | $-47.92M ▼ | $51.69M ▲ | $892K ▼ | $4.66M ▲ | $-47.95M ▼ |
| Q1-2025 | $-34.09M ▼ | $-41.38M ▼ | $-272.63M ▼ | $244.25M ▲ | $-69.76M ▼ | $-42.23M ▼ |
| Q4-2024 | $-29.46M ▼ | $-27.57M ▼ | $-1.43M ▲ | $28.8M ▲ | $-202K ▲ | $-28.02M ▼ |
| Q3-2024 | $-26.6M | $-17.36M | $-71.09M | $426K | $-88.03M | $-17.35M |
CEO
John D. Quisel
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-12-30 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 126
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Raymond James
Strong Buy
Truist Securities
Buy
HC Wainwright & Co.
Buy
Stifel
Buy
Wedbush
Outperform
BMO Capital
Outperform
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
FMR LLC
Shares:4.94M
Value:$380.4M
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC
Shares:2.14M
Value:$165.15M
BLACKROCK, INC.
Shares:2.02M
Value:$155.65M
Summary
Showing Top 3 of 177